This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ajani, J. A. Articles by Van Cutsem, E. Search for Related Content PubMed PubMed Citation Articles by Ajani, J. A. Articles by Van Cutsem, E. Related Articles Related Editorial Related Correspondence Social Bookmarking                            What's this?

Quality of Life With Docetaxel Plus Cisplatin and Fluorouracil Compared With Cisplatin and Fluorouracil From a Phase III Trial for Advanced Gastric or Gastroesophageal Adenocarcinoma: The V-325 Study Group

Jaffer A. Ajani, Vladimir M. Moiseyenko, Sergei Tjulandin, Alejandro Majlis, Manuel Constenla, Corrado Boni, Adriano Rodrigues, Miguel Fodor, Yee Chao, Edouard Voznyi, Lucile Awad, Eric Van Cutsem

From The University of Texas M.D. Anderson Cancer Center, Houston, TX; N.N. Petrov Research Institute of Oncology, St Petersburg; N.N. Blokhin Cancer Research Center; Russian Scientific Centre of Radiology, Moscow, Russia; Fundación Arturo López Pérez; Hospital Clínico Universidad de Chile, Santiago, Chile; C.H. de Pontevedra, Pontevedra, Spain; Arcispedale Santa Maria Nuova, Reggio Emilia, Italy; Hospitais da Universidade de Coimbra, Coimbra, Portugal; Taipei Veterans General Hospital, Taipei, Taiwan; Sanofi-aventis, Antony, France; and Leuven University Hospital, Leuven, Belgium

Address reprint requests to Jaffer A. Ajani, MD, Department of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Mail Stop 426, 1515 Holcombe Blvd, Houston, TX 77030; e-mail: jajani{at}mdanderson.org

Purpose Therapy of patients with advanced gastric or gastroesophageal junction cancer should provide symptom relief and improve quality of life (QOL) because most patients are symptomatic at baseline. Using validated instruments, we prospectively assessed QOL (even after completion of protocol treatment) as one of the secondary end points of the V325 phase III trial.

Patients and Methods Four hundred forty-five patients randomly received either docetaxel 75 mg/m² and cisplatin 75 mg/m² each on day 1 plus fluorouracil 750 mg/m²/d continuous infusion on days 1 to 5 every 3 weeks (DCF) or cisplatin 100 mg/m² on day 1 plus fluorouracil 1,000 mg/m²/d continuous infusion on days 1 to 5 every 4 weeks (CF). The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) and, where available, the EuroQOL EQ-5D questionnaire were administered every 8 weeks from baseline until progression and then every 3 months. Time to definitive deterioration of QOL parameters was analyzed.

Results The proportions of patients having assessable EORTC QLQ-C30 and EQ-5D questionnaires at baseline were 86.0% and 78.7% with DCF, respectively, and 89.7% and 92.8% with CF, respectively. Time to 5% deterioration of global health status (primary end point) significantly favored DCF over CF (log-rank test, P = .01). QOL was preserved longer for patients on DCF than those on CF for all time to deterioration analyses, demonstrating the statistical superiority of DCF compared with CF.

Conclusion V325 represents the largest trial with the longest prospectively controlled evaluations of QOL during protocol chemotherapy and follow-up in patients with advanced gastric or gastroesophageal junction cancer. In V325, advanced gastric or gastroesophageal junction cancer patients receiving DCF not only had statistically improved overall survival and time to tumor-progression, but they also had better preservation of QOL compared with patients receiving CF.

Supported by Sanofi-aventis.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Editorial

• Docetaxel, Cisplatin, and Fluorouracil in Gastric Cancer: Does the Punishment Fit the Crime?
  David H. Ilson
  JCO 2007 25: 3188-3190 [Full Text]

Related Correspondence

• Doubts About Whether Docetaxel, Cisplatin, Plus Fluorouracil Has Any Benefit in Advanced Gastric Cancer
  Ian E. Haines
  JCO 2007 25: 5528-5529 [Full Text]

This article has been cited by other articles:

				B. Burtness, M. Gibson, B. Egleston, R. Mehra, L. Thomas, R. Sipples, M. Quintanilla, J. Lacy, S. Watkins, J. R. Murren, et al. Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer Ann. Onc., July 1, 2009; 20(7): 1242 - 1248. [Abstract] [Full Text] [PDF]

				B. Bitik, Y. Kalpakci, E. Altan, E. Dogan, and K. Altundag Successful treatment of primary duodenal carcinoma with bilateral adrenal metastases with docetaxel-cisplatin-5-fluorouracil regimen Ann. Onc., February 1, 2009; 20(2): 394 - 395. [Full Text] [PDF]

				S.-E. Al-Batran, J. T. Hartmann, R. Hofheinz, N. Homann, V. Rethwisch, S. Probst, J. Stoehlmacher, M. R. Clemens, R. Mahlberg, M. Fritz, et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Ann. Onc., November 1, 2008; 19(11): 1882 - 1887. [Abstract] [Full Text] [PDF]

				C. Pozzo and C. Barone Is There an Optimal Chemotherapy Regimen for the Treatment of Advanced Gastric Cancer That Will Provide a Platform for the Introduction of New Biological Agents? Oncologist, July 1, 2008; 13(7): 794 - 806. [Abstract] [Full Text] [PDF]

				I. E. Haines Doubts About Whether Docetaxel, Cisplatin, Plus Fluorouracil Has Any Benefit in Advanced Gastric Cancer J. Clin. Oncol., December 1, 2007; 25(34): 5528 - 5529. [Full Text] [PDF]

				J. A. Ajani and on behalf of the V-325 participants In Reply J. Clin. Oncol., December 1, 2007; 25(34): 5529 - 5530. [Full Text] [PDF]

				D. H. Ilson Docetaxel, Cisplatin, and Fluorouracil in Gastric Cancer: Does the Punishment Fit the Crime? J. Clin. Oncol., August 1, 2007; 25(22): 3188 - 3190. [Full Text] [PDF]